Roche snaps up rest of Foundation Medicine for $2.4bn
Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.
The Swiss drugs giant said it is paying 137.00 per outstanding share in cash, equating to a total company value of $5.3 billion on a fully diluted basis.
The price represents a premium of 29 percent to FMI’s closing price on 18 June and a premium of 47 percent and 68 percent to its 30-day and 90-day volume weighted average share price on that date, respectively.
Read more: http://www.pharmatimes.com/news/roche_snaps_up_rest_of_foundation_medicine_for_$2.4bn_1240733
The Swiss drugs giant said it is paying 137.00 per outstanding share in cash, equating to a total company value of $5.3 billion on a fully diluted basis.
The price represents a premium of 29 percent to FMI’s closing price on 18 June and a premium of 47 percent and 68 percent to its 30-day and 90-day volume weighted average share price on that date, respectively.
Read more: http://www.pharmatimes.com/news/roche_snaps_up_rest_of_foundation_medicine_for_$2.4bn_1240733